Clinical Trial

A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-21.
Status change: Recruiting → Active, Not Recruiting 2026-07-06
Trial Details
NCT Number NCT06939595
Lead Sponsor Celltrion
Conditions Non Squamous Non Small Cell Lung Cancer
Enrollment 225 participants
Start Date 2025-01-30
Primary Completion 2027-02 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-08